Table 5.
Treatment of leprosy cases in Japan, 1993–2020.
| No. of drugs | Single drug | n | Two drugs | n | Three drugs | n | Four drugs | n | Five drugs | n |
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Regimen | DDS | 5 | DDS+RFP(MDT/PB) | 34 | DDS+RFP+CLF (MDT/MB) | 116 | MDT+OFLX | 4 | MDT+OFLX+CAM | 1 |
| RFP | 2 | DDS+SPFX | 1 | DDS+RFP+OFLX | 7 | MDT+CAM | 1 | |||
| CLF | 1 | DDS+OFLX | 1 | DDS+RFP+LVFX | 3 | MDT+LVFX | 14 | |||
| SPFX | 2 | CLF+SPFX | 1 | DDS+CLF+SPFX | 1 | MDT+SPFX | 2 | |||
| OFLX | 1 | RFP+CLF | 1 | DDS+CLF+LVFX | 1 | MDT+MINO | 2 | |||
| LVFX | 1 | DDS+MINO | 1 | DDS+CLF+CAM | 3 | DDS+RFP+OFLX+SPFX | 3 | |||
| DDS+CLF | 2 | DDS+RFP+SPFX | 2 | DDS+CLF+SPFX+CAM | 1 | |||||
| RFP+CLF+OFLX | 1 | DDS+RFP+OFLX+MINO | 2 | |||||||
| OFLX+MINO+CAM+LVFX | 1 | |||||||||
|
| ||||||||||
| Total number, by regimen (%) | 12 (5.5%) | 40 (18.4%) | 134 (61.8%) | 30 (13.9%) | 1 (0.5%) | |||||
|
| ||||||||||
| Total number (%) | 216 (100%) | |||||||||
CAM, clarithromycin; CLF, clofazimine; DDS, dapsone; LVFX, levofloxacin; MB, multibacillary; MDT, multidrug therapy; MINO, minocycline; OFLX; ofloxacin; PB, paucibacillary; RFP, rifampicin; SPFX, sparfloxacin.